Naglazyme and Vimzim revenues vary on a quarterly basis, primarily due to the timing of central government orders from some countries, mainly Brazil.Pipeline Update BioMarin filed regulatory applications for valrox in U.S/EU in the fourth quarter, which were accepted and granted priority review by the FDA this month.